The present invention provides compositions and methods for treating cancers with reduced or absent CDH1 using a RHOA dominant negative polypeptide or biologically active fragment thereof, and/or a nucleic acid encoding a RHOA dominant negative polypeptide or biologically active fragment thereof.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.

Lateral flow devices, methods and kits for performing lateral flow western blot assays are provided.

Compositions and methods are provided for potent mRNA vaccines for treatment of cancers with a mutation in the ras gene family. The compositions include a pharmaceutical composition comprising, or consisting essentially of, or yet further comprising mRNA molecules encoding at least one of multiple peptides of a group of somatic mutants and a pharmaceutically acceptable carrier. Methods for stimulating system immune responses and treatment are provided, including intratumoral, intravenous, intramuscular, intradermal, or subcutaneous injection of the composition as disclosed herein.

Some embodiments include a genetically engineered cell comprising a nucleic acid encoding a detectable polypeptide operably linked to the Msi1 or Msi2 promoter and genetically engineered organisms comprising these genetically engineered cells.

Disclosed are a novel method of detecting cancer, a method of screening inhibitors and anticancer agents that target cancer-related molecules, RHOA polypeptide having mutation and a polynucleotide encoding the polypeptide as a therapeutic agent for cancer, and a method of detecting cancer using the polypeptide or polynucleotide. Also disclosed are a vector and a host cell comprising the polynucleotide, a method of screening therapeutic agents for cancer comprising the polypeptide and/or the polynucleotide, and a therapeutic agent for cancer comprising siRNA having a silencing effect on RHOA mutant.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a design process comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a formulation process, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an administering step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.